ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "pregnancy"

  • Abstract Number: 2466 • 2012 ACR/ARHP Annual Meeting

    Pregnancy Outcome in Women Treated with Adalimumab for the Treatment of Rheumatoid Arthritis: The OTIS Autoimmune Diseases in Pregnancy Project

    Christina D. Chambers1, Diana L. Johnson2, Yunjun Luo1, Janina L. Jimenez1, Nicole Mirrasoul1, Elizabeth Salas1, Kenneth Lyons Jones2 and OTIS Research Group3, 1Pediatrics, University of California, San Diego, La Jolla, CA, 2University of California San Diego Department of Pediatrics, La Jolla, CA, 3Pediatrics, La Jolla

    Background/Purpose: The fully human, anti-tumor necrosis factor monoclonal antibody, adalimumab (ADA), is approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, juvenile…
  • Abstract Number: 2237 • 2012 ACR/ARHP Annual Meeting

    Application and Feasibility of Proposed Systemic Lupus Erythematosus Reproductive Health Care Quality Indicators At a Public Urban Rheumatology Clinic

    Itziar Quinzanos1, Angela Keniston2, Joann Zell3, Jinoos Yazdany4, Alyssa Nash1, Rebecca Fransen1, Jennifer Stichman1 and Joel M. Hirsh5, 1Dept Medicine, Denver Health Med Ctr, Denver, CO, 2Department of Medicine, Denver Health and Hospital Authority, Denver, CO, 3Medicine, National Jewish Health, Denver, CO, 4Medicine, University of California, San Francisco, San Francisco, CA, 5Medicine, Division of Rheumatology, Denver Health and Hospital Authority, Denver, CO

    Background/Purpose: Reproductive health quality indicators (QIs) for systemic lupus erythematosus (SLE) have recently been developed: anti-ssA, anti-ssB, and phospholipid antibody (aPL) screening prior to pregnancy;…
  • Abstract Number: 1730 • 2012 ACR/ARHP Annual Meeting

    Antiphosphatidylethanolamine Is Not Associated with Thrombosis or Pregnancy Loss in Systemic Lupus Erythematosus

    Ehtisham Akhter1, Hong Fang2, Nathalie Bardin3, Marielle San Marco3 and Michelle Petri2, 1Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Hopital de la Conception, Marseille, France

    Background/Purpose: Phosphatidylethanolamine, a zwitterionic phospholipid, is a major component of the cell plasma membrane. Phospatidylethanolamine exerts both anticoagulant and procoagulant activities in different conditions. The…
  • Abstract Number: 1734 • 2012 ACR/ARHP Annual Meeting

    Clinical Accuracy for Diagnosis of Antiphospholipid Syndrome in Systemic Lupus Erythematosus: Evaluation of 23 Possible Combinations of Antiphospholipid Antibody Specificities

    Savino Sciascia1, Veronica Murru1, Giovanni Sanna2, Dario Roccatello3, Munther A. Khamashta4 and Maria Laura Bertolaccini1, 1Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, 2Louise Coote Lupus Unit, St. Thomas' Hospital, London, United Kingdom, 3Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, 4Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom

    Background/Purpose: The clinical accuracy of testing for antiphospholipid antibody (aPL) both, as individual tests and/or in combination, is still being investigated. We aimed to identify…
  • « Previous Page
  • 1
  • …
  • 17
  • 18
  • 19
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology